Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.61 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.49 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16651823 | 1.00 | BRD4 (0.61) | BRD4BRDTBRD2BRD9BRD7 | |
| SCHEMBL29848907 | 0.91 | BRD4 (0.51) | BRD4BRDTBRD2BRD9BRD7 | |
| SCHEMBL16651536 | 0.91 | BRD4 (0.51) | BRD4BRDTBRD2BRD9BRD7 | |
| SCHEMBL16658439 | 0.88 | BRD4 (0.53) | BRD4BRDTBRD2BRD9BRD7 | |
| SCHEMBL19931050 | 0.84 | BRD4 (0.45) | BRD4BRDTBRD2BRD9BRD7 | |
| SCHEMBL19931046 | 0.84 | BRD4 (0.45) | BRD4BRDTBRD2BRD9BRD7 | |
| SCHEMBL19931035 | 0.83 | BRD4 (0.44) | BRD4BRDTBRD2BRD9BRD7 | |
| SCHEMBL19931464 | 0.82 | BRD4 (0.43) | BRD4BRDTBRD2BRD9BRD7 | |
| SCHEMBL16650438 | 0.82 | BRD4 (0.78) | BRD4BRD9 | |
| SCHEMBL16658001 | 0.80 | BRD4 (0.55) | BRD4BRDTBRD2BRD9BRD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRDT 4/4885BRD2 8/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRDT 4/4885BRD2 8/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885BRDT 4/4885BRD2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.